Get all premium features to the best stock analysis tool

Finranks

Company

About us

Contact us

[email protected]

Follow us

Instagram
Telegram
LinkedIn

All rights reserved.

Privacy Policy Terms of Conditions

Home
Markets
Screener
News
About

PROF - Profound Medical Corp. Latest News | Finranks

Home

PROF

(PROF)

NCM – Real Time Price. Currency in USD

6.19

-0.11 (-1.75%)

At close: Mar 27, 2026, 4:00 PM EDT

6.19

0.00 (0.00%)

After-hours: Mar 27, 2026, 4:04 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Profound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure™ Milestone

Profound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure™ Milestone

TORONTO, March 27, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, is pleased to announce that Texas Prostate, led by Dr. James Cochran, has achieved its 100th TULSA Procedure™ performed in Dallas Medical Center's state-of-the-art MRI suite.

Profound Medical (PROF) Surges 13.0%: Is This an Indication of Further Gains?

Profound Medical (PROF) Surges 13.0%: Is This an Indication of Further Gains?

Profound Medical (PROF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Profound Medical Corp. (PRN:CA) Discusses First Clinical Outcomes and Precision of TULSA from the CAPTAIN Trial in Prostate Cancer Transcript

Profound Medical Corp. (PRN:CA) Discusses First Clinical Outcomes and Precision of TULSA from the CAPTAIN Trial in Prostate Cancer Transcript

Profound Medical Corp. (PRN:CA) Discusses First Clinical Outcomes and Precision of TULSA from the CAPTAIN Trial in Prostate Cancer Transcript

CAPTAIN Trial Comparing Profound's MRI-Guided TULSA Procedure™ to Robotic Radical Prostatectomy Successfully Meets Primary Safety Endpoint, Preservation of Erectile Function and Urinary Continence

CAPTAIN Trial Comparing Profound's MRI-Guided TULSA Procedure™ to Robotic Radical Prostatectomy Successfully Meets Primary Safety Endpoint, Preservation of Erectile Function and Urinary Continence

– First multicenter, randomized controlled trial directly comparing a new technology to robotic RP for men with localized prostate cancer to successfully recruit to target enrollment –

Profound Medical Corp. (PRN:CA) Q4 2025 Earnings Call Transcript

Profound Medical Corp. (PRN:CA) Q4 2025 Earnings Call Transcript

Profound Medical Corp. (PRN:CA) Q4 2025 Earnings Call Transcript

Profound Medical (PROF) Reports Q4 Loss, Misses Revenue Estimates

Profound Medical (PROF) Reports Q4 Loss, Misses Revenue Estimates

Profound Medical (PROF) came out with a quarterly loss of $0.27 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.2 per share a year ago.

Earnings Preview: Profound Medical (PROF) Q4 Earnings Expected to Decline

Earnings Preview: Profound Medical (PROF) Q4 Earnings Expected to Decline

Profound Medical (PROF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Videos

No Data

There is no data to display

Press releases

Profound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure™ Milestone

Profound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure™ Milestone

TORONTO, March 27, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, is pleased to announce that Texas Prostate, led by Dr. James Cochran, has achieved its 100th TULSA Procedure™ performed in Dallas Medical Center's state-of-the-art MRI suite.

CAPTAIN Trial Comparing Profound's MRI-Guided TULSA Procedure™ to Robotic Radical Prostatectomy Successfully Meets Primary Safety Endpoint, Preservation of Erectile Function and Urinary Continence

CAPTAIN Trial Comparing Profound's MRI-Guided TULSA Procedure™ to Robotic Radical Prostatectomy Successfully Meets Primary Safety Endpoint, Preservation of Erectile Function and Urinary Continence

– First multicenter, randomized controlled trial directly comparing a new technology to robotic RP for men with localized prostate cancer to successfully recruit to target enrollment –

Johns Hopkins Medicine Treats First Commercial TULSA-PRO® Case

Johns Hopkins Medicine Treats First Commercial TULSA-PRO® Case

Profound Medical marks major milestone as the hospital launches its state-of-the-art iMRI suite to expand access to advanced prostate care Profound Medical marks major milestone as the hospital launches its state-of-the-art iMRI suite to expand access to advanced prostate care

Profound Medical Corp. Announces Closing of Private Placement

Profound Medical Corp. Announces Closing of Private Placement

TORONTO, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) is pleased to announce that it has completed its previously announced private placement of common shares to Canadian investors (the “Offering”).